Ray Dalio
PCVX icon

Ray Dalio’s Vaxcyte PCVX Stock Holding History

Ray Dalio’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$750K Buy
+12,903
New +$700K ﹤0.01% 832
2025
Q4 		– Sell
-11,855
Closed -$427K – 1155
2025
Q3 		$427K Buy
+11,855
New +$393K ﹤0.01% 942

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ray Dalio's PCVX Position: Q1 2026 in Review

Ray Dalio opened a new position in Vaxcyte (PCVX) in Q1 2026: 12,903 shares worth $750K. The stake represents ﹤0.01% of the portfolio and ranks #832 among its holdings. This is a return to the name: Ray Dalio previously reported a position in PCVX as recently as Q3 2025.

Ray Dalio first reported a position in PCVX in Q3 2025 and has held it in 2 quarters since. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Ray Dalio held 12,903 shares of Vaxcyte worth $750K as of Q1 2026.
  • Vaxcyte was a new Ray Dalio position in Q1 2026.
  • Vaxcyte made up ﹤0.01% of Ray Dalio's portfolio in Q1 2026, its #832 holding.
  • Ray Dalio first reported a position in Vaxcyte in Q3 2025 and has held it in 2 quarters since.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.